🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Nicholas Pavlidis

University of Ioannina

ORCID: 0000-0002-2195-9961
MedicineDentistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
2.3Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry

Cancer Epidemiology(2021)10.1016/j.canep.2021.102045
Top 9%
2.3DataRank
Top 9%81 citations

Elie Rassy, Jan B. Vermorken, Tarek Assi, Joseph Kattan, Stergios Boussios +2 more

Papers

Driven by 8 papers — median percentile 91. Top paper: “Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis”.

Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis

Cancer Treatment Reviews(2009)10.1016/j.ctrv.2009.05.005
N/A
5.1DataRank · unranked
128 citations

George Pentheroudakis, Georgia Salanti, Andreas D. Nearchou, Nicholas Pavlidis, Andreas Nearchou +2 more

Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis

Cancer Treatment Reviews(2007)10.1016/j.ctrv.2006.09.007
N/A
2.9DataRank · unranked
43 citations

Nicholas Pavlidis, Evangelos Paraskevaidis, John P. A. Ioannidis, Spyridon Tzioras

The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry

Cancer Epidemiology(2021)10.1016/j.canep.2021.102045
Top 9%
2.3DataRank
Top 9%81 citations

Elie Rassy, Jan B. Vermorken, Tarek Assi, Joseph Kattan, Stergios Boussios +2 more

Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis

JNCI: Journal of the National Cancer Institute(2006)10.1093/jnci/djj357
N/A
0.849DataRank · unranked
286 citations

Nicholas Pavlidis, Nikolaos P. Polyzos, John P. A. Ioannidis, Davide Mauri

Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: An overview of survival data

European Journal of Cancer(2006)10.1016/j.ejca.2005.09.026
N/A
0.434DataRank · unranked
17 citations

Nicholas Pavlidis, Evangelos Paraskevaidis, John P. A. Ioannidis, Nikolaos P. Polyzos

Levels of absolute survival benefit for systemic therapies of advanced cancer

European Journal of Cancer(2003)10.1016/s0959-8049(03)00119-9
N/A
0.396DataRank · unranked
13 citations

John P. A. Ioannidis, Nicholas Pavlidis

RESPONSE: Re: Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis

JNCI: Journal of the National Cancer Institute(2005)10.1093/jnci/dji148
N/A
0.269DataRank · unranked
5 citations

Nicholas Pavlidis, John P. A. Ioannidis, Davide Mauri

Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered

Annals of Translational Medicine(2020)10.21037/atm-20-941
N/A
0DataRank · unranked
11 citations

Tarek Assi, Stergios Boussios, Joseph Kattan, Julie Smith‐Gagen, Nicholas Pavlidis +1 more